Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Don Haut

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Sep 20, 2021 5:10pm

132 Views

Post# 33890272

RE:Don Haut

Abandoning OTENA isn’t in the cards - yet. Far from it.

Best case ... we have low and high dose opportunities.

worst case ... only high dose opportunity

mid-case ... only low dose opportunity

I see us chasing in two directions with the need for smaller P2’s for efficacy.

Just my opinion.

Doccole wrote:
I wish I could get a check to do nothing!

thoughts on October?

does ate abandon and go in a different direction?
does ate identify 2 lower doses and aim for a new trial?
does AME come back suggesting we can move to phase 3?

other?